Trials with colchicine included different CVD patients; post-MI or with chronic coronary disease. Tjerk Opstal and colleagues investigated whether the efficacy of colchicine was dependent of the time to previous ACS event.
Efficacy of colchicine compared to placebo in patients with stable coronary disease in the LoDoCo2 trial was consistent irrespective of history and timing of prior ACS.
Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.
This study found a non-linear relationship between LDL-c levels and major in-hospital bleeds, with a higher risk at lower LDL-c levels in ACS patients after PCI.
ESC 2021 After implantation of a stent in ACS patients, one-month DAPT followed by clopidogrel monotherapy did not demonstrate non-inferiority compared to 12-months DAPT for the net outcome of CV events and bleedings.
ESC 2021 Imaging findings from the HUYGENS study showed that increase in minimum fibrous cap thickness and decrease in the maximum lipid arc was greater after 12 months of evolocumab compared to placebo post-ACS.
Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.
ACC 2021 Prof. Chew summarizes the 12-months follow-up findings of the rapid TnT trial comparing two protocols of hs-troponin in patients with suspected ACS. He also gives his interpretation of the results.
This registry-based cohort study showed that one-third of patients with AF and/or VTE on a DOAC received aspirin without clear therapeutic indication. Combination therapy was associated with increased bleeding rates compared to DOAC monotherapy.
A higher relative proportion of plasma long-chain omega-3 polyunsaturated fatty acids (PUFAs) was associated with lower risk of sudden cardiac death in patients after ACS.
As an author of a Clinical Review in European Heart Journal, Niels van der Sangen discusses the options for a personalized approach of antithrombotic therapy after PCI, as described in the paper.
This subanalysis of the ODYSSEY OUTCOMES trial showed that patients with recent ACS on alirocumab with achieved LDL-c <25 mg/dL had similar risk reductions for MACE as patients with LDL-c 25-50 mg/dL.